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To evade the host immune system, several pathogens periodically change their cell-surface epitopes. In the African
trypanosomes, antigenic variation is achieved by tightly regulating the expression of a multigene family encoding a
large repertoire of variant surface glycoproteins (VSGs). Immune evasion relies on two important features: exposing a
single type of VSG at the cell surface and periodically and very rapidly switching the expressed VSG. Transcriptional
switching between resident telomeric VSG genes does not involve DNA rearrangements, and regulation is probably
epigenetic. The histone methyltransferase DOT1B is a nonessential protein that trimethylates lysine 76 of histone H3 in
Trypanosoma brucei. Here we report that transcriptionally silent telomeric VSGs become partially derepressed when
DOT1B is deleted, whereas nontelomeric loci are unaffected. DOT1B also is involved in the kinetics of VSG switching: in
DDOT1B cells, the transcriptional switch is so slow that cells expressing two VSGs persist for several weeks, indicating
that monoallelic transcription is compromised. We conclude that DOT1B is required to maintain strict VSG silencing
and to ensure rapid transcriptional VSG switching, demonstrating that epigenetics plays an important role in
regulating antigenic variation in T. brucei.
Citation: Figueiredo LM, Janzen CJ, Cross GAM (2008) A histone methyltransferase modulates antigenic variation in African trypanosomes. PLoS Biol 6(7): e161. doi:10.1371/
journal.pbio.0060161
Introduction
Post-transcriptional histone modifications play important
roles in the regulation of chromatin structure and gene
expression. Unlike acetylation, which is in general associated
with transcription activation, histone methylation can acti-
vate or repress transcription depending upon the genomic
location and the position of the modified amino acid in the
histone chain [1]. Histone methylation mainly occurs on
lysine or arginine residues that are located in the N-terminal
tails of histones H3 and H4. One exception is lysine 79 of
histone H3 (H3K79), which is located in the globular domain
of H3 and is methylated by Dot1 in yeast [2,3] and hDOT1L in
humans [4]. Very little is known about the function of H3K79
methylation. In yeast, it has a role in maintaining hetero-
chromatin, probably indirectly, by limiting the spreading of
Sir2 and Sir3 proteins into euchromatin [2]. In yeast and
mammalian cells, H3K79 methylation appears to be involved
in the detection of DNA damage [5,6] and in the development
of leukemia as a result of Hox gene activation [7].
Antigenic variation is one of the most elegant systems that
have evolved to evade host immune defenses. Trypanosoma
brucei, the unicellular parasite that causes African sleeping
sickness, expresses a single type of variant surface glycopro-
tein (VSG) at the cell surface and escapes the host immune
response by periodically exchanging it with a different VSG
(reviewed in [8]). The expressed VSG is always transcribed
from one of the ;15 bloodstream expression sites (BESs),
which are always located at telomeres [9]. To ensure
monoallelic VSG expression, only one BES is transcribed by
RNA polymerase I at any time. This active BES localizes to a
specialized extranucleolar compartment, the expression site
body (ESB), which is proposed to contain the transcription
machinery and regulatory factors that are required for
complete processing of BES transcripts [10,11]. One of the
mechanisms used to change the transcribed VSG is coordi-
nated silencing and activation of different BESs. This
stochastic process occurs at a low frequency but is very
rapid. Attempts to select cells with two simultaneously active
BESs revealed that switching intermediates are very unstable
and short-lived [12]. BES switching does not seem to require
DNA rearrangements [13], which suggests that it is mediated
by epigenetic mechanisms. Although an ISWI homologue was
shown recently to be involved in silencing BES promoter-
proximal regions [14], no well-characterized chromatin
remodeling factors are known to participate in VSG gene
regulation.
The function and structure of chromatin in T. brucei is very
poorly understood. DNA is not methylated, but it contains an
unusual modified base b-glucosylhydroxymethyluracil (J) [15],
which is mainly present in telomeric repeats and silent BESs
[16] but whose function remains unknown. The histone tails
of T. brucei are highly diverged from other well-studied
eukaryotes. Nevertheless all core histones are subject to a few
post-transcriptional modifications [17,18], including some
unusual ones such as methylation of the N-terminal alanine
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residues of H2A, H2B, and H4. Accordingly, the genome of T.
brucei contains candidates for multiple histone-modifying
enzymes (reviewed in [19]), including two disruptor-of-
telomeric silencing (DOT) methyltransferases, DOT1A and
DOT1B, that are responsible for the methylation of H3K76
(corresponding to H3K79 in yeast and mammals). DOT1A is
essential for viability and is responsible for dimethylation of
H3K76, which is important for cell cycle regulation. DOT1B
is not essential and exclusively trimethylates H3K76, a
modification apparently required for complete differentia-
tion into the insect stage of the life cycle in culture [20]. In
this study, we examined the role of DOT1B in VSG transcrip-
tional regulation. We found that DOT1B is required for
complete BES silencing but not for regulating the expression
of nontelomeric genes. When we selected for activation of a
second BES in DDOT1B cells, we observed that many cells
expressed two VSGs at their surface. With continuous
selection, switching was eventually completed. We conclude
that DOT1B is necessary for monoallelic VSG expression and
rapid switching kinetics, which demonstrates the importance
of a histone-modifying enzyme for VSG regulation.
Results
DOT1B Is Required for Complete BES Silencing
To test whether DOT1B is involved in transcriptional
regulation of BESs, we generated a cell line in which genes
conferring resistance to puromycin or G418 were introduced
immediately downstream of the promoters of two BESs
(Figure 1A), an approach first used in [21]. In a first step, the
active BES1 was tagged with a puromycin resistance gene
(PUR) downstream of the promoter. In silent BESs, tran-
scription initiates at the BES promoter but is rapidly
attenuated. This low level of transcriptional activity allowed
the random integration of the neomycin resistance gene
(NEO) immediately downstream of any ‘‘silent’’ BES pro-
moter. PCR and pulsed-field gel electrophoresis genotyping
showed that NEO had integrated at BES17. Because this
double-tagged cell line actively expresses VSG221, we named
it PN221. This reporter strain served two purposes: to
eliminate cells that spontaneously silence either BES17 or
BES1 and to place unique molecular markers into the
otherwise highly conserved DNA sequences that flank BES
promoters.
PN221 and two clones of DDOT1B PN221 were grown for
at least 5 d in the presence of a high concentration of
puromycin. This treatment killed any cells that may have
undergone a BES switch, ensuring that the active BES in the
entire population was BES1. Real-time quantitative reverse-
transcriptase PCR (RT-PCR) was used to measure the tran-
script levels of several genes. In the absence of DOT1B, the
transcripts of four silent VSGs and NEO were approximately
10-fold higher compared to those of the parental cell line,
Figure 1. Disruption of DOT1B Results in Derepression of Silent VSGs
(A) Schematic representation of PN221 genetic background, in which the
actively transcribed BES1 is tagged with a PUR and the silent BES17 is
tagged with NEO. VSG221 (MITat1.2) and VSG13 (MITat1.13) genes are
located ;50 kb downstream of the promoter (arrow) and ;1 kb
upstream of the telomere (circle).
(B) Transcript quantification by quantitative RT-PCR of WT PN221 and
two DDOT1B PN221 bloodstream clones, grown in the presence of 1 lg/
ml puromycin. VSG224 (MITat1.3), VSG800 (MITat1.18), VSG VO2 (MITat1.9),
VSG13, and NEO are genes present in silent BESs, whereas VSG221 is
actively transcribed in BES1. PAG3 is present in one procyclin locus,
which is transcriptionally downregulated in bloodstream forms. b-Tubulin
genes are present in a tandem array that is transcribed by RNA
polymerase II. Actin was used as the reference gene. Error bars indicate
the standard deviation of sextuplicates of the same cDNA sample.
(C) Relative enrichment of DDOT1B transcripts relative to the wild-type
parental reference (average of four independent measurements). When
column height is .1, DDOT1B transcript levels are higher than those in
parental PN221.
doi:10.1371/journal.pbio.0060161.g001
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Author Summary
The surface of Trypanosoma brucei, a unicellular parasite that lives in
the bloodstream of its mammalian host, is coated with glycoprotein
(VSG) molecules. To evade elimination by the immune system, this
parasite replaces its coat with one tailored from another glyco-
protein variant. Even though there are hundreds of VSG genes in the
genome, this process, called antigenic variation, works because all
are silenced except for the one that encodes the current coat. In this
work, we show that the chromatin-modifying enzyme DOT1B helps
to epigenetically regulate the number of VSGs each parasite can
have at a time at the surface and how fast each parasite can switch
from one coat to another. In parasites lacking DOT1B, silent VSG
genes become partially active and the switch from one VSG to
another slows down, allowing two different VSGs to appear on the
surface of an individual parasite at the same time. Our studies reveal
the importance of epigenetics in regulating VSG genes and provide
new insights toward the understanding of this unique survival
device.
indicating that the absence of DOT1B reduces BES silencing
(Figure 1B and 1C). The fact that both the promoter-proximal
NEO and the telomeric VSG13 of BES17 showed a similar
increase in transcript levels suggests that the entire BES17 is
partially derepressed. No significant differences were found
for the highly expressed VSG221, whose transcripts are 104–
105 more abundant than silent VSG mRNAs. No changes were
seen in mRNA levels of non-BES genes, such as actin and b-
tubulin, which are transcribed by RNA polymerase II, or for
procyclin-associated gene 3 (PAG3), whose transcription by
RNA polymerase I is largely repressed at this stage of the life
cycle [22].
Taken together, these results show that DOT1B is necessary
for complete BES silencing. Derepression due to loss of
DOT1B was not observed in a non-BES gene, which suggests
that the absence of this methyltransferase affects only a
subset of genes, including the VSGs.
DOT1B Is Required for Monoallelic VSG Expression
One of the mechanisms to change the VSG coat relies on
transcriptional silencing of one BES and activating another.
As the deletion of DOT1B affected VSG silencing, we
hypothesized that BES switching might be affected by the
absence of DOT1B. In vitro VSG switching occurs at a very
low frequency, which means that the proportion of switchers
of a population is so small that most methods cannot detect
them. To overcome this problem, positive drug selection was
used to select for cells that stochastically activated BES17. In
the original PN221 reporter strain, the vast majority of cells
are puromycin-resistant and G418-sensitive (unpublished
data). When high concentrations of G418 (75 lg/ml) were
added to 23 106 cells of 5 to 12 PN221 parental or DDOT1B
subclones, most cells died. Approximately 8 G418-resistant
clones were obtained per subclone after 1–2 wk of incuba-
tion, which suggests that parental and DDOT1B clones switch
at a similar frequency. Nine days after adding G418, protein
dot-blot analysis showed that all G418-resistant clones from
parental cells, but only a fraction of DDOT1B clones,
expressed VSG13 (Figure 2A). Three classes of DDOT1B
clones were detected (Figure 2A): those that exclusively
expressed VSG221 (Class I), those that expressed VSG221
and VSG13 (Class II), and those that exclusively expressed
VSG13 (Class III). With continuous G418 selection, VSG221-
expressing clones became VSG221/VSG13 double-expressing
clones, and these eventually expressed only VSG13 (Figure
2B). These results indicated that DDOT1B cells are capable of
switching from BES1 (VSG221) to BES17 (VSG13) at a similar
frequency as wild-type cells, but the switchover proceeds
more slowly.
To study VSG expression in individual cells, indirect
immunofluorescence analysis (IFA) was performed using
purified anti-VSG221 and anti-VSG13. IFA on a mixture of
PN221 and PN13 confirmed that both anti-VSG sera are
specific (Figure 2C, upper panel). All cells in DDOT1B Class II
expressed VSG221, but some also expressed VSG13 (Figure
2C, middle and lower panels), indicating that the VSG coat is
composed of more than one type of VSG. Both VSGs seem to
be uniformly distributed over the cell surface. The number of
detectable double-expressers varied with time and between
clones, ranging from 10–60% of the total number of cells.
From these results we conclude that DOT1B is required for
monoallelic VSG expression.
The presence of two VSGs at the surface of a cell suggested
that two BESs might be simultaneously active. Because both
BESs were tagged with selectable markers, we could use high-
level resistance to puromycin or G418 as a measure of the
Figure 2. DOT1B is Required for Rapid Switching and for Monoallelic Expression
(A) VSG expression of G418-resistant clones after 9 d of drug selection. Ten parental PN and 17 DDOT1B PN clones were analyzed by protein dot blot
with anti-VSG221 and anti-VSG13 purified sera. The same analysis was repeated in three independent experiments, on an average of 15 G418-resistant
clones.
(B) Variation of VSG expression with time. The same clones described above were periodically analyzed by dot blot for a total of 50 d. The percentage of
clones that are exclusively recognized by anti-VSG13 is plotted.
(C) Non-cross-reactivity of anti-VSG221 and anti-VSG13 were tested by IFA on a 50:50 mixture of wild-type PN221 and PN13 cells (upper panels). The
same sera and conditions were used for IFA of DDOT1B Class II clones (middle and bottom panels). DNA was detected with DAPI (blue). Scale bars: 10
lm (upper and medium panels), 2 lm (lower panel).
doi:10.1371/journal.pbio.0060161.g002
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transcriptional status of BES1 or BES17, respectively. Before
selection with G418, VSG221-expresssing parental and
DDOT1B cells were puromycin-resistant and G418-sensitive,
which indicated that BES1 was active and BES17 silent. After
G418 selection, switched parental cells were sensitive to
puromycin, but DDOT1B Class I and DDOT1B Class II cells
were resistant. In fact, both classes of DDOT1B cells were able
to grow in the presence of both puromycin and G418 with a
doubling time (;7 h) only slightly longer than that of wild-
type cells (Figure S1). In contrast, Class III cells were
puromycin-sensitive. Pulsed-field gel electrophoresis and
PCR analysis showed that no DNA rearrangements had
occurred (unpublished data).
Taken together, these results (summarized in Table 1) show
that DOT1B is necessary to maintain monoallelic expression
in the cell population. In the absence of DOT1B, BES
switching can still occur, but more slowly. A stable inter-
mediate stage can be detected in which BES1 and BES17 are
simultaneously active, conferring resistance to both drugs
and exposing two VSGs at the surface.
DOT1B Is Required for Rapid Changes in BES Expression
Closer analysis of IFA images revealed that DDOT1B Class
II cells stained uniformly with anti-VSG221, but the intensity
of anti-VSG13 staining varied widely from cell to cell. Flow
cytometry was used to quantify cell-surface VSG. Parental
cells exclusively expressing VSG221 (PN221) stained intensely
with anti-VSG221 but not detectably with anti-VSG13 (Figure
3A, panel a). As expected, the reverse was true for parental
cells expressing VSG13 (PN13) (Figure 3A, panel b). These
results show that both antibodies are specific and can be used
to analyze surface VSG levels in a mixed population of living
cells.
The fluorescent-activated cell sorting (FACS) profile of
DDOT1B Class I (Figure 3A, panel c) was very similar to that
of PN221 cells, except that 5% of the cells were slightly
VSG13-positive. The average intensity of this staining was
very low (;20 units), which probably explains why dot-blot
analysis of Class I clones failed to detect VSG13. In two
independent DDOT1B Class II clones (Figure 3A, panels d
and e), the proportion of cells with detectable VSG13 was
larger (28% and 21%) and detectable by dot-blot analysis
(unpublished data). As observed by IFA, the VSG221 staining
intensity of double-stained cells was constant and identical to
that of parental PN221 cells, whereas VSG13 intensity varied
between cells (Figure 3A, panel d). Interestingly, among
DDOT1B double-expressers, the VSG13 intensity never
reached the average intensity of PN13 cells (;800 units),
suggesting that the levels of surface VSG13 in double-
expressing cells are below wild-type levels. After a variable
number of days of G418 selection, a small distinct population
appeared with VSG13 intensity as high as single VSG13-
expressing PN13 cells and no detectable VSG221 (Figure 3A,
panel e). This population of VSG13 single-expressers invar-
iably became increasingly prominent over the double-
expressers until it comprised the entire population. At this
point, the VSG expression profile of these clones was
identical to that of Class III clones (Figure 3A, panel f), which
are undistinguishable from that of PN13 single-expresser
(Figure 3A, panel b). These results show that, albeit slowly,
DDOT1B cells eventually reach a VSG profile identical to that
of a wild-type VSG13-expressing clone. It is noteworthy that,
in the different classes of DDOT1B G418-resistant cells, we
never detected a population with intermediate levels of
VSG221, suggesting that BES1 is fully transcribed until it is
rapidly and completely silenced.
To confirm that the levels of surface VSG and mRNA are
correlated, RNA and protein levels in independent DDOT1B
clones with variable levels of VSG13 expression were
quantified by northern blotting and FACS analysis (Figure
3B). The correlation between VSG13 mRNA and surface
protein levels was very high (þ0.99), indicating that surface
VSG staining reflects steady-state mRNA levels and suggests
that the DDOT1B switching intermediates simultaneously
transcribe two BESs.
Partial BES Activation Is Stably Inherited
After prolonged G418 selection, a population of cells
exclusively expressing VSG13 appears among DDOT1B Class
II clones, and this population eventually outgrows the double-
expressing cells. To confirm that these pure VSG13 express-
ers originate from a double-expressing cell, FACS was used to
sort only those cells that were brightly stained with both anti-
VSG221 and anti-VSG13 (marked with a square in Figure 4A).
These cells were subcloned and cultivated for 60 d in a high
concentration of G418. FACS analysis showed that, in all
subclones, a population of pure VSG13-expressers emerged
between 8 and 24 d and gradually became more abundant,
eventually leading to a homogeneous population of VSG13
expressers (Figure 4B). These results show that a DDOT1B
double-expressing cell is capable of completing the switching
process between BES1 and BES17, which confirms that a
double-expresser is a switching intermediate.
To test whether partial activation of BES17 was dependent
on drug selection, double-expressers were sorted, subcloned,
and cultured without antibiotics for 30 d. Except for a larger
Table 1. Phenotype of Wild-Type and DDOT1B Double-Tagged Clones
Cell Line VSG Expressed Drug Rresistance Expression Status
PURO G418 BES1 BES17
PN221 VSG221 þþþ – Active Silent
PN13 VSG13 – þþþ Silent Active
DDOT1B PN221 VSG221 þþþ – Active Derepressed
DDOT1B Double-Expresser (Class I and II) VSG221 and VSG13 þþþ þþþ Active Range of activity
DDOT1B PN13 (Class II and III) VSG13 – þþþ Derepressed Active
doi:10.1371/journal.pbio.0060161.t001
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proportion of cells with undetectable levels of VSG13
between 5 and 30 d postsorting, the FACS profile of the
sorted cells (Figure 4C) was very similar to the profile of the
starting population (Figure 4A). When a high concentration
of G418 was added back to the medium, no cell death or
growth lag was observed, and cells continued to grow
exponentially, only slightly slower than in the absence of
drug (Figure 4D). These results showed that partial activation
of BES17 persisted and was stably inherited in the absence of
drug pressure.
Other VSG Genes Remain 10-Fold Derepressed in Double
Expressers
If DOT1B only affects the kinetics of specific drug-selected
BES switching, then we expected VSG genes in other BES to
remain repressed in DDOT1B double-expressers. Transcript
levels of silent telomeric VSGs 224, 800, and VO2 were
measured by quantitative RT-PCR. Three DDOT1B double-
expressing clones expressing different levels of VSG13 were
compared to DDOT1B single-expressers (one DDOT1B
PN221 and two DDOT1B PN13 clones). Figure 5 shows that
transcript levels of silent VSGs in the three DDOT1B double-
expressing clones were not significantly different from the
levels in the single-VSG-expressing clones DDOT1B PN221
and DDOT1B PN13. The control gene, PAG3, also remained
essentially unchanged. VSG221 transcript levels in DDOT1B
double-expressers were identical to those of DDOT1B PN221,
in agreement with the FACS data, which showed that BES1
remained fully active in these two types of clones (Figure 3A).
In contrast, in DDOT1B PN13, VSG221 transcripts were, on
average, 33 104-fold lower, which reflects the rapid silencing
of BES1. These results confirm that silent VSGs remain largely
repressed in DDOT1B double-expressers, displaying only the
basal 10-fold derepression described previously for DDOT1B
PN221 expressers (Figure 1).
Partially Active BES17 Is Not Found in a New
Extranucleolar Body
The active BES localizes in the extranucleolar ESB [10]. It
has been proposed that limited access to the ESB and its
singularity could be the reason why only one BES is fully
active. As DDOT1B double-expressers have two active BESs,
we asked whether a second ESB was present in these cells. To
count ESBs, we epitope-tagged RPB6z, a well-characterized
subunit of the RNA polymerase I complex that localizes in the
nucleolus and the ESB [23]. An N-terminally hemagglutinin
(HA)-tagged RPB6z has been shown to be fully functional in
the T. brucei procyclic form and to not interfere with Pol I
activity in vitro [24]. HA-RPB6z-tagged cell lines were
generated in parental and DDOT1B cells. PCR and western
blotting were used to confirm correct genomic integration
and expression levels (unpublished data). DDOT1B double-
expressers were subsequently selected with G418 and char-
acterized by FACS (unpublished data). We chose DDOT1B
double-expressing clones in which at least 40% of the cells
showed 40–50% of maximum VSG13 expression. IFA with an
anti-HA antibody revealed one nucleolus in practically all
nondividing cells and at least one extranucleolar spot in 20–
46% of both wild-type and DDOT1B cells (Figure 6). We
detected no statistically significant difference in the number
of cells containing one extranucleolar body between parental
and DDOT1B double-expressers. Approximately 10% of
DDOT1B double-expressers displayed two small extranucleo-
lar bodies. Surprisingly, the same percentage was found in
parental cells, eliminating the possibility that the two
extranucleolar spots reflect the location of the two active
BES of double-expressers. The nature of a second extra-
nucleolar site remains unclear: it could reflect the replication
of the ESB or the presence of an occasional rDNA tran-
scription site outside the nucleolus. In summary, we observed
no extra RPB6z-containing site in DDOT1B double-express-
ers. Labeling Pol I transcripts with bromo-UTP also failed to
reveal an additional ESB (Figure S2). These results suggest
Figure 3. Two BESs Are Simultaneously Active in DDOT1B Double-
Expressers
(A) Living cells were stained with Alexa Fluor 488 anti-VSG221 and Alexa
Fluor 647 anti-VSG13 and analyzed by FACS. Intensities of VSG221 and
VSG13 staining are shown on the x and y axes, respectively. Percentages
refer to the proportion of the total cells in a given quadrant. Each panel
represents an independent clone: parental PN221 and PN13 clones
(panels a and b), one DDOT1B Class I clone (panel c), two DDOT1B Class II
clones (panels d and e), and one DDOT1B Class III clone (panel f).
(B) VSG RNA and protein levels in multiple DDOT1B clones were
measured by northern and FACS analysis and are indicated as a
percentage of the levels in wild-type PN13 (sample #10). Five
independent DDOT1B Class II clones expressing different levels of
VSG13 were selected based on the quantification by FACS analysis.
Pearson correlation between RNA and protein series is þ0.99.
doi:10.1371/journal.pbio.0060161.g003
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that the partially active BES17 is located in an existing RNA
Pol I site, such as the nucleolus or the ESB.
Discussion
Monoallelic transcription of a single member of a multigene
family is a phenomenon seen in several eukaryotes. In
mammals, for example, a single olfactory receptor gene is
selected from a family of ;1,000 [25]. For several pathogenic
protozoa, this mechanism is the basis for antigenic variation
(reviewed in [26]). For example, the human malaria parasite
Plasmodium falciparum transcribes only one of ;60 var genes on
the surface of infected red blood cells [27]. To switch from one
gene to another, most organisms use epigenetic transcriptional
control mechanisms that are poorly characterized. In this
study, we provide the first evidence that a well-characterized
histone methyltransferase, DOT1B, affects antigenic variation
in T. brucei on three levels: maintenance of complete BES
silencing, rapid transcriptional switching between BESs, and,
as a consequence, VSG monoallelic expression.
We previously reported that RT-PCR detected no VSG
derepression in DDOT1B cells [20]. Here, we used a more
sensitive approach, quantitative RT-PCR, to quantify the
transcript levels of silent VSGs. In the absence of DOT1B,
silent BESs were 10-fold derepressed in single- and double-
expressers, indicating that DOT1B is required for maximum
repression of silent BESs. Importantly, disruption of DOT1B
does not seem to affect the expression of all genes: no
changes were detected in the transcript levels of non-BES
genes b-tubulin or actin, which are transcribed by RNA
polymerase II, or PAG3, whose transcription by RNA
polymerase I is partially repressed at this stage of the life
cycle [22]. This selectivity is consistent with what has been
described in Saccharomyces cerevisiae, in which loss of Dot1 only
derepresses telomeric marker genes and—to a lesser extent—
the HM loci [28]. In yeast, this derepression is most likely an
indirect consequence of the redistribution of Sir proteins
throughout the genome [2]. Although telomeric silencing has
Figure 4. DDOT1B Double-Expressers Are Stable Switching Intermediates
(A) A population of DDOT1B Class II cells brightly stained with anti-VSG221 and anti-VSG13 (square) was sorted and subcloned by limiting dilution either
in the presence of 100 lg/ml G418 (60 d) or in the absence of any drug (30 d).
(B) Six clones grown in the presence of G418 were submitted to FACS analysis every 8 d to follow the proportion of cells that exclusively express VSG13.
(C) After 5 and 30 d without any antibiotics, VSG221 and VSG13 expression was measured by FACS. The profile of one representative clone is shown.
(D) After 30 d without antibiotic, cells were diluted in 25 or 75 lg/ml G418, and cell growth was followed for 7 d.
doi:10.1371/journal.pbio.0060161.g004
Figure 5. Silent VSGs Remain 10-Fold Derepressed in DDOT1B Double-
Expressers
Transcript levels of three independent DDOT1B double-expresser clones
expressing different levels of VSG13 were compared to one DDOT1B
PN221 and two DDOT1B PN13 single-expressers, by quantitative RT-PCR.
VSGs 224, 800, and VO2 are present in silent BESs. VSG221 is maximally
transcribed in DDOT1B PN221 and DDOT1B double-expresser clones and
silent in DDOT1B PN13. VSG13 is present in BES17, which is partially
active at different levels in the three DDOT1B double-expressers and fully
active in DDOT1B PN13. PAG3 is present in one procyclin locus, which is
transcriptionally downregulated in bloodstream forms. b-tubulin was
used as the reference gene. Transcripts levels are indicated relative to
DDOT1B PN221.
doi:10.1371/journal.pbio.0060161.g005
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been described in T. brucei [29], no causal proteins have been
identified. Nevertheless, it is tempting to speculate that
disruption of DOT1B causes a similar cascade of events in T.
brucei, which results in an indirect derepression of telomeric
BESs but not of other loci.
Although silent BESs are partially derepressed in DDOT1B
cells, the number of G418-resistant clones arising is similar to
that of wild-type cells, indicating that partial derepression of
a silent BES does not affect the BES switching frequency. This
is consistent with previous observations showing that the
rate-limiting step of a BES switch is silencing of the
previously active BES rather than activation of a new one
[30,31]. After 1 wk of selection, all parental G418-resistant
clones were puromycin-sensitive and exclusively expressed
VSG13, indicating that BES1 was completely and rapidly
silenced and BES17 was fully activated. In contrast, after the
same time, most DDOT1B G418-resistant clones were
resistant to both puromycin and G418 and expressed
maximum levels of VSG221 and variable levels of VSG13,
indicating that two BESs were simultaneously transcribed. To
our knowledge, so far, this is the only gene whose disruption
leads to the loss of monoallelic VSG expression.
A previous study showed, by using a double-BES-tagged cell
line similar to ours, that double-resistant clones could be
obtained in which ;65% of the cells simultaneously ex-
pressed two VSGs at the surface [12]. There are two important
features that distinguish these cells from DDOT1B double-
resistant clones. First, DDOT1B double-resistant clones are
obtained by selecting for resistance to only one antibiotic
(G418), whereas double-resistant wild-type clones could only
be obtained by simultaneously selecting with two antibiotics.
Second, DDOT1B double-resistant cells are stable and
inheritable for at least 30 d in the absence of drug selection,
whereas wild-type double-resistant clones rapidly lose double
resistance and revert to a 50:50 mixture of trypanosomes with
only one of the two marked BESs active. We propose,
however, that both studies isolated a comparable switching
intermediate, but whereas this is a transient state in wild-type
cells, it is stable and inheritable in the absence of DOT1B.
On the basis of FACS and quantitative RT-PCR, we were
able to quantify the activities of BES1 and BES17 in switching
intermediates. Whereas BES1 remained 100% active, BES17
showed variable expression levels. Interestingly, we never
found DDOT1B double-expressers that expressed wild-type
levels of VSG13, indicating that, although the entire BES17 is
transcribed, the level of transcription is not maximal. These
results suggest an important VSG regulation mechanism that
strictly prevents two BESs from being fully transcribed but
that is permissive to one BES being fully active and another
BES being partially active. We do not know how such a
limitation is imposed, but it is possible that it relies on the
competition for a limiting transcription factor present in the
ESB [10]. This nuclear compartmentalization hypothesis is
consistent with our RNA polymerase I localization studies.
We observed no difference in the number of RNA Pol I sites
between wild-type and DDOT1B cells, suggesting that there is
a spatial restriction of Pol I transcription sites in the nucleus.
We speculate that BES17 is expressed either in the nucleolus
or in the unique ESB, close to BES1. This model is consistent
with what was observed in double-resistant wild-type clones,
in which the two rapidly switching active BESs often were
found in close proximity in the nucleus [12], and with the
localization of a partially active BES at the periphery of the
nucleolus [32]. Despite the localization in a Pol I competent
compartment, BES17 is only partially activated, which
suggests that another limiting factor is missing. We cannot
exclude the possibility that the levels of expression of BES17
are too low to allow the detection of an additional RPB6z site,
but this seems unlikely because, for these experiments, we
chose DDOT1B double-expressers where at least 40% of the
cells were displaying 40–50% of maximal VSG13 expression.
If BES17 is transcribed by half the amount of Pol I complexes
than BES1, then we should still be able to detect a bright spot.
Figure 6. Frequency of Extranucleolar Spots Is Identical in Parental and
DDOT1B Double-Expresser HA-RPB6z Clones
(A) Examples of four nondividing bloodstream cells expressing HA-
RPB6z, detected by HA.11 monoclonal antibody. DNA was detected with
DAPI (blue). Scale bar: 2 lm.
(B) Quantification of cells containing 0, 1, or 2 extranucleolar spots in
parental and DDOT1B double-expresser (DE) HA-RPB6z clones. The total
number of cells and the percentage in each category is indicated for
three independent experiments. The average values from the three
experiments are shown as a histogram.
doi:10.1371/journal.pbio.0060161.g006
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After 8–24 d of continuous G418 selection, switching
intermediates eventually express only VSG13, suggesting that
the competition for a limiting factor is resolved in some
double-resistant cells. Consequently, this leads to the rapid
silencing of BES1 and full activation of BES17. BES switching
is most likely a complex mechanism that involves several
events in a precise order. Nothing is known about the
intermediates of a BES switch, which means that we cannot
exclude the possibility that double-resistant cells are not a
switching intermediate but simply a fraction of the popula-
tion selected by drug pressure. If the latter was true, then one
would predict that the number of G418-resistant clones
would be higher in DDOT1B because the drug would select
not only for VSG13 expressers but also for the fraction of
cells with higher transcription levels in BES17. Also, if drug
double-expressers were a product of drug selection, then,
when pressure is removed, one would predict that the double-
resistance phenotype should be lost, as demonstrated by [12]
and discussed above. None of these predictions is consistent
with our data, suggesting that double-expressers are more
likely switching intermediates and, consequently, DOT1B is
involved in the kinetics of switching.
The VSG profile detected by FACS indicates that DDOT1B
double-expressers have the same amount of VSG221 molecules
at the surface as a VSG221 expresser and an extra 5–90% of
the total VSG13 usually present in a VSG13 expresser. As VSG
molecules form a tightly packed surface coat, we speculate that
the volume of the cells might be slightly larger to accom-
modate the excess of VSG molecules. A similar observation
was made previously, when two VSGs were simultaneously
expressed at the same levels as one normally is [33]. By means
that we can only speculate upon, the cells seem able to
accommodate up to twice as much VSG expression.
Several studies suggest that silencing of a previously active
BES and activation of a new BES are tightly coupled
(reviewed in [34]), which predicts the existence of a sensing
mechanism that facilitates cross-talk between BESs. It
remains unclear what step of switching is affected in
DDOT1B: activation of BES17 or silencing of BES1. If DOT1B
is a transcription activator, as shown in cancer cells [7], then
its absence may interfere with BES17 activation. In this
scenario, double-resistant cells are a consequence of a
defective BES17 activation that leads, due to incomplete
cross-talk between BESs, to BES1 remaining fully active.
Alternatively, the effects of DOT1B depletion may be an
indirect consequence of a disruption of telomeric silencing.
In this case, the absence of DOT1B may interfere with
silencing of BES1, and by cross-talk, a second BES is
temporarily prevented from being fully activated. Interest-
ingly, no population of DDOT1B double-expressers ever was
found with intermediate levels of VSG221, indicating that,
even in the absence of DOT1B, BES1 either remains fully
active or becomes fully silenced. These results indicate that
DOT1B is not implicated in the all-or-nothing property of
the machinery that silences a previously active BES.
BES switching probably requires the ordered recruitment
of complex machinery that recognizes a specific chromatin
configuration and remodels it to establish a new chromatin
structure in the two involved BESs. In this study, we showed
that a histone-modifying enzyme is part of this machinery,
which unveils the importance of chromatin modifications in
antigenic variation of African trypanosomes.
Materials and Methods
Strains and media. T. brucei bloodstream-form parasites (strain
Lister 427, antigenic type MiTat 1.2, clone 221a) [35] were cultured at
37 8C in HMI-9 medium [36]. The ‘‘single marker’’ cell line expresses
T7 RNA polymerase and the tet repressor, allowing inducible
expression of ectopic genes under control of the T7 promoter and
tet operator [37]. Stable transfections were performed as described
using either a BTX electroporator [38] or an AMAXA Biosystems
nucleofector. In the latter, 40 million cells were resupended in T-cell
solution and transfected using program X-001. DOT1B alleles
(Accession Number: XM_001218759) were deleted using a PCR-
based approach that conferred resistance to hygromycin and
phleomycin as described previously [39]. Loss of both alleles was
confirmed by PCR and western blotting with an anti-H3K79me3
antibody [20]. In drug sensitivity assays, 104 cells were diluted in 10 ml
of HMI-9 containing either 100 lg/ml of G418 or 1 lg/ml of
puromycin. Cell growth was determined 48 h later. To measure
population doubling time, cell growth was monitored for at least 8 d
under similar conditions.
Generation of a switching-reporter strain and tagged proteins. An
in situ switching reporter strain was derived from wild-type clone
221a, in which PUR and NEO were integrated downstream of
different BES promoters. Integration of PUR in BES1 was obtained
by transfecting 221a cells with a construct (pLF12) consisting of three
fragments cloned into pBluescriptSKIIþ in the following 5’ to 3’
order: the upstream promoter region (UP), PUR flanked by the
Aldolase splice acceptor site and 3’ UTR, and the downstream
promoter region (DP) (Figure S3). UP is the 1590-bp fragment
spanning from the 50-bp repeat array to 240 bp downstream of the
ES transcription start site. DP is the 1150-bp region spanning from
287 bp downstream of the ES transcription start site to ESAG7. The
BES1/PUR cell line was subsequently transfected with pLF13, which
introduced NEO in an identical position of a second random BES.
After multiple clones were genotyped, the cell line chosen as in situ
switch reporter integrated PUR at the actively transcribed BES1 and
NEO at the silent BES17. Because it expresses VSG221, this cell line
was named PN221.
An influenza HA tag was introduced at the 5’ end of one of the
RPB6z alleles by transfection with pLF96, derived from a pPURO-
HA-RPB6z construct [24] in which the PURO cassette was replaced by
a HindIII to SacI fragment encoding blasticidin resistance, flanked
upstream by the hsp70 intergenic region and downstream by the b-
tubulin intergenic region. HA-RPB6z-tagged cell lines were generated
in single marker and DDOT1B backgrounds. Single marker was
preferred over wild-type 221 for future uses of the tagged cell line.
Real-time quantitative RT-PCR and northern blot analysis. Total
RNA was extracted from ;108 bloodstream-form cells with RNA
STAT-60 (TEL-TEST, Inc.), following the manufacturer’s instructions.
Approximately 20 lg of RNA was DNAse-treated, phenol–chloro-
form-extracted, and ethanol-precipitated. cDNA was synthesized with
oligodT(18) primers using the StrataScript First Strand Synthesis
System (Stratagene). Approximately 5 ll of three serial dilutions of
cDNA (1:10, 1:40, and 1:160) was used for quantitative RT-PCR with
SYBR green (Applied Biosystems). Amplification reactions were
performed in duplicates in an Applied Biosystems 7900HT. Primer
sequences are listed in Table S1. Relative levels of gene expression
were measured using the comparative cycle threshold CT method
(User Bulletin 2, ABI, http://www.appliedbiosystems.com/), using b-
tubulin or actin as reference genes. For northern analysis, 3 lg of
total RNA was resolved on a 1.5% formaldehyde agarose gel,
transferred to a nylon membrane, and detected with a random
primer-labelled specific probe. Sequences are available upon request.
Anti-VSG antibodies. Anti-VSG13 (also known as MITat1.13) serum
was obtained by immunizing a rabbit with purified native VSG13, as
described previously [40]. Rabbit anti-VSG13 and rabbit and chicken
anti-VSG221 (MITat1.2) were depleted of glycosylphosphatidylinosi-
tol-related VSG cross-reacting-determinant (CRD) antibodies by
passing through an affinity column of a different VSG [41]. For
FACS, live cells were stained with affinity-purified antibodies directly
conjugated to Alexa Fluor 488 (anti-VSG221) or Alexa Fluor 647
(anti-VSG13).
VSG immunodetection. VSG expression was assayed by dot
blotting. Briefly, 2–33 106 trypanosomes were concentrated into 10
ll of HMI-9 medium by centrifugation at 2,500g for 4 min.
Approximately 2 ll of cell suspension was dropped onto a Hybond-
ECL membrane (Amersham), previously incubated in PBS pH 7.2 for
5 min. After being air-dried for 5 min, the membrane was processed
as for western blotting. Primary anti-VSG antibodies were detected
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with horseradish-peroxidase-conjugated sheep anti-rabbit antibodies
(Amersham).
Immunofluorescence. For VSG visualization, cells were fixed in 2%
(w/v) formaldehyde at room temperature for 10 min. After being
washed twice in PBS containing 2 mM EDTA, cells were settled onto
aminopropyltriethoxysilane-coated coverslips. Immobilized cells
were blocked in PBG (PBS containing 0.2% cold fish gelatin (Sigma)
and 0.5% BSA) and incubated with chicken DCRD anti-VSG221 and
rabbit DCRD anti-VSG13 sera for 1 h followed by tetramethylrhod-
amine isothiocyanate-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch Laboratories) or Alexa Fluor 488-conjugated goat
anti-chicken IgG (Invitrogen) for 1 h. Cells were mounted in DAPI-
containing antifade medium Vectashield (Vector Laboratories) and
analyzed with a Nikon Optiphot microscope. The same protocol was
followed for HA-RPB6z detection, except cells were fixed in 0.5% (w/
v) formaldehyde for 5 min. After settling onto coverslips, cells were
permeabilized with 0.2% NP40 for 5 min. The HA tag was detected
with a monoclonal anti-HA.11 antibody, clone 16B12 (Covance).
Coverslips were examined using DeltaVision deconvolution micro-
scopy (Applied Precision).
FACS analysis and cell sorting. For quantification of cell-surface
VSG, 106 cells were centrifuged in a previously chilled microtube at
2,500g for 4 min at 4 8C. Cells were resuspended in 100 ll of cold
HMI-9 to which Alexa Fluor 488 anti-VSG221 and/or Alexa Fluor 647
anti-VSG13 conjugated antibodies had been added. After 20 min of
incubation at 4 8C with gentle shaking, cells were washed three times
in cold HMI-9, resuspended in cold HMI-9, and immediately analyzed
on a FACSort flow cytometer (Becton Dickinson Biosciences). Data
were processed with FlowJo software (Tree Star). Approximately 43
106 cells were similarly stained for sorting on a FACSAria cell-sorter
(Becton Dickinson Biosciences). Sorted cells were immediately
washed twice in HMI-9 containing 400 U/ml penicillin and 400 lg/
ml streptomycin. Approximately 5, 100, or 2,000 cells/ml were
transferred to 24-well plates without or with 100 lg/ml G418. The
VSG profiles of subclones were analyzed after 6–8 d.
Supporting Information
Figure S1. Growth of a DDOT1B Class II Clone under Different Drug
Regimes
Found at doi:10.1371/journal.pbio.0060161.sg001 (1.1 MB AI).
Figure S2. Frequency of Pol I Transcript Foci Is Identical in Parental
and DDOT1B Double-Expresser Clones
(A) Examples of four nondividing bloodstream cells in which
transcripts were labeled with bromo-UTP and visualized by IFA. a-
Amanitin inhibits transcription by RNA Pol II and III, allowing the
exclusive detection of RNA polymerase I transcripts. DNA was
detected with DAPI (blue). Scale bar: 2 lm.
(B) Quantification of Pol I transcript foci in parental and DDOT1B
double-expresser clones, in different stages of the cell cycle. An
average of 40 cells/clone was counted.
Found at doi:10.1371/journal.pbio.0060161.sg002 (1.5 MB PDF).
Figure S3. Constructs to Generate Reporter Strain
pLF12 and pLF13 constructs used to introduce drug-selectable
markers into BESs. Dashed lines represent the targeting sequences
UP and DP. Gray boxes represent the aldolase splice-acceptor site
and 3’ UTR. pLF12 and pLF13 differ only in the drug-selectable
marker. Genotyping of clones obtained after transfection of both
plasmids into wild-type 221 cells led to the identification of the
PN221 cell line in which pLF12 had targeted the actively transcribed
BES1 and pLF13 the silent BES17.
Found at doi:10.1371/journal.pbio.0060161.sg003 (1.1 MB AI).
Table S1. Primer Sequences Used for Quantitative RT-PCR
Found at doi:10.1371/journal.pbio.0060161.st001 (1.1 MB AI).
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